Treatment of Cushing disease: overview and recent findings

References

• ArnaldiGAngeliAAtkinsonABDiagnosis and complications of Cushing’s syndrome: a consensus statementJ Clin Endocrinol Metab200388125593560214671138
   PubMed Web of Science ®Google Scholar
• PivonelloRde MartinoMCde LeoMLombardiGColaoACushing’s syndromeEndocrinol Metab Clin North Am200837113514918226734
   PubMed Web of Science ®Google Scholar
• CanalisEMazziottiGGiustinaABilezikianJPGlucocorticoidinduced osteoporosis: pathophysiology and therapyOsteoporos Int200718101319132817566815
   PubMed Web of Science ®Google Scholar
• LindholmJJuulSJørgensenJOIncidence and late prognosis of Cushing’s syndrome: a population-based studyJ Clin Endocrinol Metab200186111712311231987
   PubMed Web of Science ®Google Scholar
• ManciniTKolaBManteroFBoscaroMArnaldiGHigh cardiovascular risk in patients with Cushing’s syndrome according to 1999 WHO/ISH guidelinesClin Endocrinol (Oxf)200461676877715579193
   PubMed Web of Science ®Google Scholar
• ArnaldiGManciniTPolentaBBoscaroMCardiovascular risk in Cushing’s syndromePituitary20047425325616416038
   PubMedGoogle Scholar
• MazziottiGAngeliABilezikianJPCanalisEGiustinaAGlucocorticoidinduced osteoporosis: an updateTrends Endocrinol Metab200617414414916678739
   PubMed Web of Science ®Google Scholar
• ManciniTDogaMMazziottiGGiustinaACushing’s syndrome and bonePituitary20047424925216010458
   PubMedGoogle Scholar
• BillerBMGrossmanABStewartPMTreatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statementJ Clin Endocrinol Metab20089372454246218413427
   PubMed Web of Science ®Google Scholar
• WagenmakersMANetea-MaierRTvan LindertEJTimmersHJGrotenhuisJAHermusARRepeated transsphenoidal pituitary surgery (TS) via the endoscopic technique: a good therapeutic option for recurrent or persistent Cushing’s disease (CD)Clin Endocrinol (Oxf)200970227428018616702
   PubMed Web of Science ®Google Scholar
• AtkinsonABKennedyAWiggamMIMcCanceDRSheridanBLong-term remission rates after pituitary surgery for Cushing’s disease: the need for long-term surveillanceClin Endocrinol (Oxf)200563554955916268808
   PubMed Web of Science ®Google Scholar
• HammerGDTyrrellJBLambornKRTranssphenoidal microsurgery for Cushing’s disease: initial outcome and long-term resultsJ Clin Endocrinol Metab200489126348635715579802
   PubMed Web of Science ®Google Scholar
• HofmannBMHlavacMKreutzerJGrabenbauerGFahlbuschRSurgical treatment of recurrent Cushing’s diseaseNeurosurgery20065861108111816723890
   PubMed Web of Science ®Google Scholar
• SoninoNZieleznyMFavaGAFalloFBoscaroMRisk factors and long-term outcome in pituitary-dependent Cushing’s diseaseJ Clin Endocrinol Metab1996817264726528675592
   PubMed Web of Science ®Google Scholar
• MampalamTJTyrrellJBWilsonCBTranssphenoidal microsurgery for Cushing disease. A report of 216 casesAnn Intern Med198810964874932843068
   PubMed Web of Science ®Google Scholar
• LiuJKFleseriuMDelashawJBJrCiricISCouldwellWTTreatment options for Cushing disease after unsuccessful transsphenoidal surgeryNeurosurg Focus2007233E817961031
   PubMedGoogle Scholar
• VanceMLCushing’s disease: radiation therapyPituitary2009121111418437577
   PubMed Web of Science ®Google Scholar
• EstradaJBoronatMMielgoMThe long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing’s diseaseN Engl J Med199733631721778988897
   PubMed Web of Science ®Google Scholar
• JagannathanJSheehanJPPouratianNLawsERSteinerLVanceMLGamma knife surgery for Cushing’s diseaseJ Neurosurg2007106698098717564168
   PubMedGoogle Scholar
• CastinettiFRégisJDufourHBrueTRole of stereotactic radiosurgery in the management of pituitary adenomasJ Clin Endocrinol Metab201064214223
   Google Scholar
• CastinettiFNagaiMMorangeILong-term results of stereotactic radiosurgery in secretory pituitary adenomasJ Clin Endocrinol Metab20099493400340719509108
   PubMed Web of Science ®Google Scholar
• MinnitiGTraishDAshleySGonsalvesABradaMRisk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 yearsJ Clin Endocrinol Metab200590280080415562021
   PubMed Web of Science ®Google Scholar
• PollockBENippoldtTBStaffordSLFooteRLAbboudCFResults of stereotactic radiosurgery in patients with hormone-producing pituitary adenomas: factors associated with endocrine normalizationJ Neurosurg200297352553012296634
   PubMed Web of Science ®Google Scholar
• ChowJTThompsonGBGrantCSFarleyDRRichardsMLYoungWFJrBilateral laparoscopic adrenalectomy for corticotrophin-dependent Cushing’s syndrome: a review of the Mayo Clinic experienceClin Endocrinol (Oxf)200868451351917970770
   PubMed Web of Science ®Google Scholar
• AssiéGBahurelHCosteJCorticotroph tumor progression after adrenalectomy in Cushing’s Disease: a reappraisal of Nelson’s syndromeJ Clin Endocrinol Metab200792117217917062771
   PubMed Web of Science ®Google Scholar
• ManciniTCasanuevaFFGiustinaAHyperprolactinemia and prolactinomasEndocrinol Metab Clin North Am20083716799viii18226731
   PubMed Web of Science ®Google Scholar
• GiustinaAChansonPBronsteinMDA consensus on criteria for cure of acromegalyJ Clin Endocrinol Metab20109573141314820410227
   PubMed Web of Science ®Google Scholar
• MelmedSCasanuevaFCavagniniFConsensus statement: medical management of acromegalyEur J Endocrinol2005153673774016322377
   PubMed Web of Science ®Google Scholar
• SchteingartDEDrugs in the medical treatment of Cushing’s syndromeExpert Opin Emerg Drugs200914466167119939210
   PubMed Web of Science ®Google Scholar
• SoninoNThe use of ketoconazole as an inhibitor of steroid productionN Engl J Med1987317138128183306384
   PubMed Web of Science ®Google Scholar
• SoninoNBoscaroMMedical therapy for Cushing’s diseaseEndocrinol Metab Clin North Am199928121122210207692
   PubMed Web of Science ®Google Scholar
• MorrisDGrossmanAThe medical management of Cushing’s syndromeAnn N Y Acad Sci200297011913312381547
   PubMed Web of Science ®Google Scholar
• SoninoNBoscaroMPaolettaAManteroFZiliottoDKetoconazole treatment in Cushing’s syndrome: experience in 34 patientsClin Endocrinol (Oxf)19913543473521752063
   PubMed Web of Science ®Google Scholar
• EngelhardtDWeberMMTherapy of Cushing’s syndrome with steroid biosynthesis inhibitorsJ Steroid Biochem Mol Biol19944946261267
   Web of Science ®Google Scholar
• StrickerBHBlokAPBronkhorstFBvan ParysGEDesmetVJKetoconazole-associated hepatic injury. A clinicopathological study of 55 casesJ Hepatol1986333994063559147
   PubMed Web of Science ®Google Scholar
• GrossBAMindeaSAPickAJChandlerJPBatjerHHMedical management of Cushing diseaseNeurosurg Focus2007233E1017961023
   PubMedGoogle Scholar
• VerhelstJATrainerPJHowlettTAShort and long-term responses to metyrapone in the medical management of 91 patients with Cushing’s syndromeClin Endocrinol (Oxf)19913521691781657460
   PubMed Web of Science ®Google Scholar
• MisbinRICanaryJWillardDAminoglutethimide in the treatment of Cushing’s syndromeJ Clin Pharmacol1976161112645651
   Web of Science ®Google Scholar
• ChildDFBurkeCWBurleyDMReesLHFraserTRDrug controlled of Cushing’s syndrome: combined aminoglutethimide and metyrapone therapyActa Endocrinol (Copenh)197682330341179256
   PubMedGoogle Scholar
• SantenRJMisbinRIAminoglutethimide: review of pharmacology and clinical usePharmacotherapy198112951206765487
   PubMed Web of Science ®Google Scholar
• TerzoloMAngeliAFassnachtMAdjuvant mitotane treatment for adrenocortical carcinomaN Engl J Med2007356232372238017554118
   PubMed Web of Science ®Google Scholar
• LutonJPMahoudeauJABouchardPTreatment of Cushing’s disease by O,p’DDD. Survey of 62 casesN Engl J Med19793009459464215912
   PubMed Web of Science ®Google Scholar
• SchteingartDETsaoHSTaylorCIMcKenzieAVictoriaRTherrienBASustained remission of Cushing’s disease with mitotane and pituitary irradiationAnn Intern Med19809256136196247946
   PubMed Web of Science ®Google Scholar
• MaherVMTrainerPJScoppolaAAndersonJVThompsonGRBesserGMPossible mechanism and treatment of o,p’DDD-induced hypercholesterolaemiaQ J Med1992843056716791480741
   PubMedGoogle Scholar
• LeibaSWeinsteinRShindelBThe protracted effect of o,p’-DDD in Cushing’s disease and its impact on adrenal morphogenesis of young human embryoAnn Endocrinol (Paris)198950149532729882
   PubMed Web of Science ®Google Scholar
• HerrmannBLMitchellASallerBTranssphenoidal hypophysectomy of a patient with an ACTH-producing pituitary adenoma and an “empty sella” after pretreatment with etomidateDtsch Med Wochenschr2001126923223411256037
   PubMedGoogle Scholar
• MettauerNBrierleyJA novel use of etomidate for intentional adrenal suppression to control severe hypercortisolemia in childhoodPediatr Crit Care Med2009103e37e4019433940
   PubMedGoogle Scholar
• GreeningJEBrainCEPerryLAEfficient short-term control of hypercortisolaemia by low-dose etomidate in severe paediatric Cushing’s diseaseHorm Res200564314014316192738
   PubMed Web of Science ®Google Scholar
• MezeyEHunyadyBMitraSCell specific expression of the sst2 A and sst5 somatostatin receptors in the rat anterior pituitaryEndocrinology199813914144199421441
   PubMed Web of Science ®Google Scholar
• KraicerJGajewskiTCMoorBCRelease of pro-opiomelanocortin-derived peptides from the pars intermedia and pars distalis of the rat pituitary: effect of corticotrophin-releasing factor and somatostatinNeuroendocrinology19854153633732865690
   PubMed Web of Science ®Google Scholar
• LambertsSWZuyderwijkJden HolderFvan KoetsveldPHoflandLStudies on the conditions determining the inhibitory effect of somatostatin on adrenocorticotropin, prolactin and thyrotropin release by cultured rat pituitary cellsNeuroendocrinology198950144502569172
   PubMed Web of Science ®Google Scholar
• SchonbrunnAGlucocorticoids down-regulate somatostatin receptors on pituitary cells in cultureEndocrinology19821104114711546120829
   PubMed Web of Science ®Google Scholar
• van der HoekJWaaijersMvan KoetsveldPMDistinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cellsAm J Physiol Endocrinol Metab20052892E27828715769796
   PubMed Web of Science ®Google Scholar
• StallaGKBrockmeierSJRennerUOctreotide exerts different effects in vivo and in vitro in Cushing’s diseaseEur J Endocrinol199413021251318130885
   PubMed Web of Science ®Google Scholar
• HoflandLJvan der HoekJFeeldersRThe multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5Eur J Endocrinol2005152464565415817922
   PubMed Web of Science ®Google Scholar
• BatistaDLZhangXGejmanRThe effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomasJ Clin Endocrinol Metab200691114482448816940446
   PubMed Web of Science ®Google Scholar
• GolaMBonadonnaSMazziottiGAmatoGGiustinaAResistance to somatostatin analogs in acromegaly: an evolving concept?J Endocrinol Invest2006291869316553040
   PubMed Web of Science ®Google Scholar
• AmatoGMazziottiGRotondiMLong-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegalyClin Endocrinol (Oxf)2002561657111849248
   PubMed Web of Science ®Google Scholar
• MelmedSColaoABarkanAAcromegaly Consensus Group. Guidelines for acromegaly management: an updateJ Clin Endocrinol Metab20099451509151719208732
   PubMed Web of Science ®Google Scholar
• AmbrosiBBochicchioDFerrarioRColomboPFagliaGScreening tests for Cushing’s syndromeClin Endocrinol (Oxf)19903368098112096012
   PubMedGoogle Scholar
• InvittiCde MartinMBrunaniAPioliniMCavagniniFTreatment of Cushing’s syndrome with the long-acting somatostatin analogue SMS 201-995 (sandostatin)Clin Endocrinol (Oxf)19903232752812160871
   PubMed Web of Science ®Google Scholar
• LambertsSWUitterlindenPKlijnJMThe effect of the long-acting somatostatin analogue SMS 201-995 on ACTH secretion in Nelson’s syndrome and Cushing’s diseaseActa Endocrinol (Copenh)198912067607662543178
   PubMedGoogle Scholar
• TyrrellJBLorenziMGerichJEForshamPHInhibition by somatostatin of ACTH secretion in Nelson’s syndromeJ Clin Endocrinol Metab197540611251127166089
   PubMed Web of Science ®Google Scholar
• PetriniLGasperiMPilosuRMarcelloAMartinoELong-term treatment of Nelson’s syndrome by octreotide: a case reportJ Endocrinol Invest19941721351398006335
   PubMed Web of Science ®Google Scholar
• KelestimurFUtasCOzbakirOSelçukluAKandemirOOzcanNThe effects of octreotide in a patient with Nelson’s syndromePostgrad Med J19967284353548746287
   PubMed Web of Science ®Google Scholar
• BoscaroMLudlamWHAtkinsonBTreatment of pituitarydependent Cushing’s disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trialJ Clin Endocrinol Metab200994111512218957506
   PubMed Web of Science ®Google Scholar
• MazziottiGFlorianiIBonadonnaSTorriVChansonPGiustinaAEffects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studiesJ Clin Endocrinol Metab20099451500150819208728
   PubMed Web of Science ®Google Scholar
• GiustinaAVeldhuisJDPathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the humanEndocr Rev19981967177979861545
   PubMed Web of Science ®Google Scholar
• GiustinaAWehrenbergWBThe role of glucocorticoids in the regulation of growth hormone secretion: mechanisms and clinical significanceTrends Endocrinol Metab19923830631118407116
   PubMed Web of Science ®Google Scholar
• de BruinCFeeldersRALambertsSWHoflandLJSomatostatin and dopamine receptors as targets for medical treatment of Cushing’s SyndromeRev Endocr Metab Disord20091029110218642088
   PubMed Web of Science ®Google Scholar
• SaiardiABorrelliEAbsence of dopaminergic control on melanotrophs leads to Cushing’s-like syndrome in miceMol Endocrinol1998128113311399717839
   PubMedGoogle Scholar
• CroughsRJKoppeschaarHPvan’t VerlaatJWMcNicolAMBromocriptine-responsive Cushing’s disease associated with anterior pituitary corticotroph hyperplasia or normal pituitary glandJ Clin Endocrinol Metab19896824954982537335
   PubMed Web of Science ®Google Scholar
• LambertsSWde LangeSAStefankoSZAdrenocorticotropin-secreting pituitary adenomas originate from the anterior or the intermediate lobe in Cushing’s disease: differences in the regulation of hormone secretionJ Clin Endocrinol Metab19825422862916274899
   PubMed Web of Science ®Google Scholar
• PivonelloRFeroneDde HerderWWDopamine receptor expression and function in corticotroph pituitary tumorsJ Clin Endocrinol Metab20048952452246215126577
   PubMed Web of Science ®Google Scholar
• IllouzFDubois-GinouvesSLaboureauSRohmerVRodienPUse of cabergoline in persisting Cushing’s diseaseAnn Endocrinol (Paris)200667435335617072242
   PubMed Web of Science ®Google Scholar
• MiyoshiTOtsukaFTakedaMEffect of cabergoline treatment on Cushing’s disease caused by aberrant adrenocorticotropin-secreting macroadenomaJ Endocrinol Invest200427111055105915754738
   PubMed Web of Science ®Google Scholar
• PivonelloRde MartinoMCCappabiancaPThe medical treatment of Cushing’s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline inpatients unsuccessfully treated by surgeryJ Clin Endocrinol Metab200994122323018957500
   PubMed Web of Science ®Google Scholar
• ZanettiniRAntoniniAGattoGGentileRTeseiSPezzoliGValvular heart disease and the use of dopamine agonists for Parkinson’s diseaseN Engl J Med20073561394617202454
   PubMed Web of Science ®Google Scholar
• FeeldersRAde BruinCPereiraAMPasireotide alone or with cabergoline and ketoconazole in Cushing’s diseaseN Engl J Med2010362191846184820463350
   PubMed Web of Science ®Google Scholar
• HeaneyAPFernandoMYongWHMelmedSFunctional PPARgamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomasNat Med20028111281128712379847
   PubMed Web of Science ®Google Scholar
• GiraldiFPScaroniCArvatEEffect of protracted treatment with rosiglitazone, a PPARgamma agonist, in patients with Cushing’s diseaseClin Endocrinol (Oxf)20066421922416430724
   PubMed Web of Science ®Google Scholar
• AmbrosiBDall’AstaCCannavoSEffects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing’s diseaseEur J Endocrinol200415117317815296471
   PubMed Web of Science ®Google Scholar
• SuriDWeissREEffect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing’s diseaseJ Clin Endocrinol Metab2005901340134615585550
   PubMed Web of Science ®Google Scholar
• ManciniTMazziottiGDogaMVertebral fractures in males with type 2 diabetes treated with rosiglitazoneBone200945478478819527806
   PubMed Web of Science ®Google Scholar
• LabeurMPaez-PeredaMArztEStallaGKPotential of retinoic acid derivatives for the treatment of corticotroph pituitary adenomasRev Endocr Metab Disord200910210310918604646
   PubMed Web of Science ®Google Scholar
• de MarinisLBianchiAFuscoALong-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSAPituitary200710322723217484056
   PubMed Web of Science ®Google Scholar
• CastinettiFFassnachtMJohanssenSMerits and pitfalls of mifepristone in Cushing’s syndromeEur J Endocrinol200916061003101019289534
   PubMed Web of Science ®Google Scholar
• FalloFPaolettaATonaFBoscaroMSoninoNResponse of hypertension to conventional antihypertensive treatment and/or steroidogenesis inhibitors in Cushing’s syndromeJ Intern Med199323465955988258751
   PubMed Web of Science ®Google Scholar
• FalloFSoninoNBarzonLEffect of surgical treatment on hypertension in Cushing’s syndromeAm J Hypertens19969177808834710
   PubMed Web of Science ®Google Scholar
• BieringHKnappeGGerlHLochsHPrevalence of diabetes in acromegaly and Cushing syndromeActa Med Austriaca2000271273110812460
   PubMedGoogle Scholar
• ManelliFGiustinaAGlucocorticoid-induced osteoporosisTrends Endocrinol Metab200011798510707047
   PubMed Web of Science ®Google Scholar
• HermusARSmalsAGSwinkelsLMBone mineral density and bone turnover before and after surgical cure of Cushing’s syndromeJ Clin Endocrinol Metab199580285928657559865
   PubMed Web of Science ®Google Scholar
• ManningPJEvansMCReidIRNormal bone mineral density following cure of Cushing’s syndromeClin Endocrinol (Oxf)1992362292341563076
   PubMed Web of Science ®Google Scholar
• di SommaCPivonelloRLocheSEffect of 2 years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing’s disease: a prospective studyClin Endocrinol (Oxf)20035830230812608935
   PubMed Web of Science ®Google Scholar
• CanalisEGiustinaAGlucocorticoid-induced osteoporosis: summary of a workshopJ Clin Endocrinol Metab200186125681568511739419
   PubMed Web of Science ®Google Scholar
• CanalisEBilezikianJPAngeliAGiustinaAPerspectives on glucocorticoid-induced osteoporosisBone200434459359815050888
   PubMed Web of Science ®Google Scholar
• LuisettoGZangariMCamozziVBoscaroMSoninoNFalloFRecovery of bone mineral density after surgical cure, but not by ketoconazole treatment, in Cushing’s syndromeOsteoporos Int20011295696011804023
   PubMed Web of Science ®Google Scholar
• di SommaCColaoAPivonelloREffectiveness of chronic treatment with alendronate in the osteoporosis of Cushing’s diseaseClin Endocrinol (Oxf)1998486556629666879
   PubMed Web of Science ®Google Scholar
• CanalisEGiustinaABilezikianJPMechanisms of anabolic therapies for osteoporosisN Engl J Med2007357990591617761594
   PubMed Web of Science ®Google Scholar
• MazziottiGBianchiABonadonnaSIncreased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapyJ Bone Miner Res200621452052816598371
   PubMed Web of Science ®Google Scholar
• LaneNESanchezSModinGWGenantHKPieriniEArnaudCDBone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trialJ Bone Miner Res20001594495110804025
   PubMed Web of Science ®Google Scholar
• ManelliFCarpinteriRBossoniSGrowth hormone in glucocorticoid-induced osteoporosisFront Horm Res20023017418311892265
   PubMed Web of Science ®Google Scholar
• GiustinaABussiARJacobelloCWehrenbergWBEffects of recombinant human growth hormone (GH) on bone and intermediary metabolism in patients receiving chronic glucocorticoid treatment with suppressed endogenous GH response to GH-releasing hormoneJ Clin Endocrinol Metab19958011221297829600
   PubMed Web of Science ®Google Scholar
• AngeliAGuglielmiGDovioAHigh prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient studyBone200639225325916574519
   PubMed Web of Science ®Google Scholar
• TerzoloMBossoniSAlíAGrowth hormone (GH) responses to GH-releasing hormone alone or combined with arginine in patients with adrenal incidentaloma: evidence for enhanced somatostatinergic toneJ Clin Endocrinol Metab20008531310131510720081
   PubMed Web of Science ®Google Scholar
• GiustinaABarkanAChansonPPituitary Society; European Neuroendocrine Association. Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adultsJ Endocrinol Invest200831982083818997495
   PubMed Web of Science ®Google Scholar
• VeldmanRGFrölichMPincusSMVeldhuisJDRoelfsemaFApparently complete restoration of normal daily adrenocorticotropin, cortisol, growth hormone, and prolactin secretory dynamics in adults with Cushing’s disease after clinically successful transsphenoidal adenomectomyJ Clin Endocrinol Metab200085114039404611095430
   PubMed Web of Science ®Google Scholar
• DegerbladMBrismarKRähnTThorénMThe hypothalamuspituitary function after pituitary stereotactic radiosurgery: evaluation of growth hormone deficiencyJ Intern Med2003253445446212653875
   PubMed Web of Science ®Google Scholar
• Pecori GiraldiFAndrioliMde MarinisLSignificant GH deficiency after long-term cure by surgery in adult patients with Cushing’s diseaseEur J Endocrinol2007156223323917287413
   PubMed Web of Science ®Google Scholar
• HöybyeCRagnarssonOJönssonPJClinical features of GH deficiency and effects of 3 years of GH replacement in adults with controlled Cushing’s diseaseEur J Endocrinol2010162467768420089548
   PubMed Web of Science ®Google Scholar
• DogaMBonadonnaSGolaMMazziottiGGiustinaAGrowth hormone deficiency in the adultPituitary20069430531117077947
   PubMedGoogle Scholar
• DogaMBonadonnaSGolaMCurrent guidelines for adult GH replacementRev Endocr Metab Disord200561637015711916
   PubMed Web of Science ®Google Scholar
• ColsonABrookeAMWalkerDGrowth hormone deficiency and replacement in patients with treated Cushing’s Disease, prolactinomas and non-functioning pituitary adenomas: effects on body composition, glucose metabolism, lipid status and bone mineral densityHorm Res200666625726716914933
   PubMedGoogle Scholar
• WebbSMMoDLambertsSWInternational HypoCCS Advisory BoardMetabolic, cardiovascular, and cerebrovascular outcomes in growth hormone-deficient subjects with previous Cushing’s disease or non-functioning pituitary adenomaJ Clin Endocrinol Metab201095263063820022992
   PubMed Web of Science ®Google Scholar